<DOC>
	<DOCNO>NCT00198354</DOCNO>
	<brief_summary>The addition chemotherapy lung cancer surgery consider standard care . Solid data support postoperative chemotherapy result available preoperative setting . To define time perioperative chemotherapy offer best survival improvement , IFCT 0002 study conduct France .</brief_summary>
	<brief_title>Stage I/II NSCLC Perioperative Chemotherapy</brief_title>
	<detailed_description>In multicenter study , patient randomize receive either two preoperative chemotherapy cycle plus two additional preoperative cycle respond chemotherapy , two preoperative plus two postoperative cycle case response .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Histologically cytologically NSCLC stade I II Resectable disease WHO performance status 2 less NSCLC stage III IV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>